May 17, 2022

Chairman Dr Harry Brunjes contributes to post-covid breathing research in The Lancet

By now, many of us have had (or know someone who has had) Covid, but for some people, it can cause long term illness and disability, which is increasingly appreciated as a global challenge.

Kuro Health is proud and honoured to be the major sponsor of ENO Breathe, a pioneering breathing and wellbeing programme led by the English National Opera (ENO) in partnership with Imperial College Healthcare Trust. Specifically for people struggling with breathlessness and associated anxiety due to long covid, ENO Breathe has treated over 1000 patients nationwide, working with over 60 NHS Trusts.

Last month, the first randomised control trial for people diagnosed with post-covid syndrome or long covid was conducted on the ENO Breathe programme and published in The Lancet Respiratory Medicine, the world’s top-ranking respiratory medical journal. The trial concluded that the breathing program improved elements of breathlessness in people with persisting symptoms after Covid-19. These findings are hugely important in proving the programme’s effectiveness and in the context of supporting people with post-covid syndrome or long covid.

Dr Harry Brunjes, Chair of ENO, said: “We are extremely proud that ENO Breathe has been evidenced to aid the recovery of the people with long-covid.  We are enormously grateful to our partners at Imperial for their dedicated work in developing this programme”. 

Read the full Lancet article

Find out more about using ENO Breathe

Watch the ITN News article and hear stories from patients who have benefitted from ENO Breathe

Back to news